Navigation Links
Developing gene therapy to fight blindness
Date:7/29/2009

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease. The therapy has been shown to restore lost vision in animal models of retinitis pigmentosa (RP). Their work is being funded in part by a $1.5 million grant from the Prince Salman Center for Disability Research in Saudi Arabia, where the recessive gene mutation that leads to the eye disease RP has been found in children from several families.

The study is being led by Kang Zhang, MD, PhD, professor of ophthalmology at the University of California, San Diego School's Shiley Eye Center and director of the UCSD Institute for Genomic Medicine, and Fowzan Alkuraya, MD, senior clinical scientist and head of developmental genetics unit at King Faisal Specialist Hospital and Research Center, Saudi Arabia.

RP is a type of hereditary retinal dystrophy, a group of inherited disorders in which abnormalities of the photoreceptor rods and cones lead to progressive visual loss. Rods and cones are specialized light-sensitive nerve cells that line the retina. They collect light and then send nerve signals that the brain interprets as vision. Rods facilitate black and white vision and are used mainly at night. During the day, humans depend on cones for color vision.

In people with the genetic mutations that cause RP, rods and cone cells die. Affected individuals first experience defective dark adaptation or "night blindness," followed by reduction of the peripheral visual field known as tunnel vision, sometimes followed by loss of central vision late in the course of the disease. RP affects one in 3,000 to 4,000 people in the United States.

The planned clinical approach of this research trial involves a receptor protein called MERTK that is expressed in the retinal pigment epithelium, the pigmented cell layer just outside the retina that closely interacts with photoreceptors in the maintenance of visual function. Patients with loss of MERTK function have a defect in phagocytosis a mechanism used to remove pathogens and cell debris. As a result of this defect, debris accumulates between the photoreceptors and retinal pigment epithelium, resulting in death of photoreceptors and loss of vision.

The researchers plan to deliver the MERTK gene in a viral vector a carrier commonly used to deliver genetic material to treat these cells in order to restore function of photoreceptors. Using a rodent model of RP with a similar MERTK mutation, the researchers have demonstrated in proof-of-concept studies that viral vector delivery of MERTK corrects the mutant gene and restores vision.

The eye is an ideal place for gene therapy because it's an "immune-privileged site," meaning that the eye is able to tolerate the introduction of foreign cells with a minimal, if any, inflammatory immune response, according to Zhang.

The research team's next step is to show that such gene therapy is safe in further animal studies, to be conducted in China, along with additional rat studies that will be conducted at UC San Diego and at the University of Florida.

Once safety for the procedure has been shown, the team hopes to proceed to a human clinical trial in seven patients identified in Saudi Arabia, perhaps as early as spring of 2010.

The same type of vector has been successfully tested in both animals and humans for a similar type of early-onset retinal degeneration called Leber's congenital amaurosis.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Scientists Track Impact of DNA Damage in the Developing Brain
2. The risk of developing deep vein thrombosis during a flight is often overestimated
3. Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
4. Brazil proves developing countries can use generic medicines to fight HIV/AIDS epidemic
5. Researchers identify individuals at risk for developing colon cancer
6. Rare sheep could be key to better diagnostic tests in developing world, says Stanford study
7. Living Alone Increases Odds of Developing Dementia
8. Research output in developing countries reveals 194 percent increase in five years
9. Leeds engineers developing bullet proof vests from cement
10. Prospect Therapeutics Inc.s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers
11. Caucasians are at higher risk of developing Ewings sarcoma than other races
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The Commission for ... the Board of Commissioners. Individuals interested in volunteer board service are encouraged to ... clinical practice settings and across allied health to contribute to its mission and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... ongoing community involvement program, introduces a new charity campaign to raise funds for ... now being accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is ...
(Date:2/11/2016)... ... , ... Be Well Medical Group (Be Well) is pleased to ... 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a ... convenience of their homes, offices or at the practices’ local office. It is also ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for ... health and wellness best practices in the past couple of decades, and food ... American Heart Month, which acts as an exceptional opportunity to revise food labels ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology: